Aberrant overexpression of CD14 on granulocytes sensitizes the innate immune response in mDia1 heterozygous del(5q) MDS

Blood

Volumn 124, Issue 5, 2014, Pages 780-790

  Keerthivasan, Ganesan ^a   Mei, Yang ^a   Zhao, Baobing ^a   Zhang, Ling ^b   Harris, Chad E ^c   Gao, Juehua ^a   Basiorka, Ashley A ^b   Schipma, Matthew J ^d   McElherne, James ^a   Yang, Jing ^a   Verma, Amit K ^e   Pellagatti, Andrea ^f   Boultwood, Jacqueline ^f   List, Alan F ^b   Williams, David A ^c   Ji, Peng ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^f JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD14 ANTIGEN; LENALIDOMIDE; LIPOPOLYSACCHARIDE; MESSENGER RNA; TOLL LIKE RECEPTOR 4;

5Q- SYNDROME; ANIMAL EXPERIMENT; ARTICLE; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; CELL LINEAGE; CELL STIMULATION; CONTROLLED STUDY; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GRANULOCYTE; HETEROZYGOSITY LOSS; HUMAN; HYPERSENSITIVITY; INNATE IMMUNITY; KNOCKOUT MOUSE; MOUSE; MYELODYSPLASTIC SYNDROME; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; UPREGULATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; ANTIGENS, CD14; BONE MARROW CELLS; CARRIER PROTEINS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 5; FEMALE; GENE EXPRESSION REGULATION; GRANULOCYTES; HETEROZYGOTE; HUMANS; IMMUNITY, INNATE; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, KNOCKOUT; MYELODYSPLASTIC SYNDROMES; RNA, MESSENGER; TOLL-LIKE RECEPTOR 4;

EID: 84905082105     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-01-552463     Document Type: Article

References (40)

1. Beris P, Georgiou G. Overview of myelodysplastic syndromes. Semin Hematol. 2012;49(4):287-294.
2. Cazzola M, Della Porta MG, Travaglino E, Malcovati L. Classification and prognostic evaluation of myelodysplastic syndromes. Semin Oncol. 2011;38(5):627-634.
3. Swerdlow SH, Campo E, Harris NL, et al., eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Geneva, Switzerland: World Health Organization; 2008.
4. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117(19):5019-5032.
5. Heim S, Mitelman F. Chromosome abnormalities in the myelodysplastic syndromes. Clin Haematol. 1986;15(4):1003-1021. (Pubitemid 17014721)
6. Ebert BL. Deletion 5q in myelodysplastic syndrome: a paradigm for the study of hemizygous deletions in cancer. Leukemia. 2009;23(7):1252-1256.
7. Ebert BL, Pretz J, Bosco J, et al. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature. 2008;451(7176):335-339.
8. Barlow JL, Drynan LF, Hewett DR, et al. A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q- syndrome. Nat Med. 2010;16(1):59-66.
9. Joslin JM, Fernald AA, Tennant TR, et al. Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders. Blood. 2007;110(2):719-726. (Pubitemid 47105411)
10. Liu TX, Becker MW, Jelinek J, et al. Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation. Nat Med. 2007;13(1):78-83. (Pubitemid 46067389)
11. Stoddart A, Wang J, Fernald AA, Karrison T, Anastasi J, Le Beau MM. Cell intrinsic and extrinsic factors synergize in mice with haploinsufficiency for Tp53, and two human del (5q) genes, Egr1 and Apc. Blood. 2014;123(2):228-238.
12. Starczynowski DT, Kuchenbauer F, Argiropoulos B, et al. Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype. Nat Med. 2010;16(1):49-58.
13. Kumar MS, Narla A, Nonami A, et al. Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5q- syndrome. Blood. 2011;118(17):4666-4673.
14. Eisenmann KM, Dykema KJ, Matheson SF, et al. 5q- myelodysplastic syndromes: chromosome 5q genes direct a tumor-suppression network sensing actin dynamics. Oncogene. 2009;28(39):3429-3441.
15. Faix J, Grosse R. Staying in shape with formins. Dev Cell. 2006;10(6):693-706. (Pubitemid 43779105)
16. Shi Y, Zhang J, Mullin M, Dong B, Alberts AS, Siminovitch KA. The mDial formin is required for neutrophil polarization, migration, and activation of the LARG/RhoA/ROCK signaling axis during chemotaxis. J Immunol. 2009;182(6):3837-3845.
17. Sakata D, Taniguchi H, Yasuda S, et al. Impaired T lymphocyte trafficking in mice deficient in an actin-nucleating protein, mDia1. J Exp Med. 2007;204(9):2031-2038. (Pubitemid 47360865)
18. Tanizaki H, Egawa G, Inaba K, et al. Rho-mDia1 pathway is required for adhesion, migration, and T-cell stimulation in dendritic cells. Blood. 2010;116(26):5875-5884.
19. Peng J, Kitchen SM, West RA, Sigler R, Eisenmann KM, Alberts AS. Myeloproliferative defects following targeting of the Drf1 gene encoding the mammalian diaphanous related formin mDia1. Cancer Res. 2007;67(16):7565-7571. (Pubitemid 47287487)
20. Cazzola M. Flow cytometry immunophenotyping for diagnosis of myelodysplastic syndrome. Haematologica. 2009;94(8):1041-1043.
21. Haziot A, Tsuberi BZ, Goyert SM. Neutrophil CD14: biochemical properties and role in the secretion of tumor necrosis factor-alpha in response to lipopolysaccharide. J Immunol. 1993;150(12):5556-5565. (Pubitemid 23180670)
22. Gioannini TL, Teghanemt A, Zhang D, et al. Isolation of an endotoxin-MD-2 complex that produces Toll-like receptor 4-dependent cell activation at picomolar concentrations. Proc Natl Acad Sci USA. 2004;101(12):4186-4191. (Pubitemid 38405904)
23. da Silva Correia J, Soldau K, Christen U, Tobias PS, Ulevitch RJ. Lipopolysaccharide is in close proximity to each of the proteins in its membrane receptor complex. transfer from CD14 to TLR4 and MD-2. J Biol Chem. 2001;276(24):21129-21135.
24. Starczynowski DT, Karsan A. Innate immune signaling in the myelodysplastic syndromes. Hematol Oncol Clin North Am. 2010;24(2):343-359.
25. Esplin BL, Shimazu T, Welner RS, et al. Chronic exposure to a TLR ligand injures hematopoietic stem cells. J Immunol. 2011;186(9):5367-5375.
26. Young NS. Hematopoietic cell destruction by immune mechanisms in acquired aplastic anemia. Semin Hematol. 2000;37(1):3-14. (Pubitemid 30080243)
27. Sejas DP, Rani R, Qiu Y, et al. Inflammatory reactive oxygen species-mediated hemopoietic suppression in Fancc-deficient mice. J Immunol. 2007;178(8):5277-5287. (Pubitemid 46595313)
28. Giagounidis A, Mufti GJ, Fenaux P, Germing U, List A, MacBeth KJ. Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes. Ann Hematol. 2014;93(1):1-11.
29. List A, Dewald G, Bennett J, et al; Myelodysplastic Syndrome-003 Study Investigators. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355(14):1456-1465. (Pubitemid 44511560)
30. List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med. 2005;352(6):549-557. (Pubitemid 40204668)
31. Corral LG, Haslett PA, Muller GW, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol. 1999;163(1):380-386. (Pubitemid 29295864)
32. Velegraki M, Papakonstanti E, Mavroudi I, et al. Impaired clearance of apoptotic cells leads to HMGB1 release in the bone marrow of patients with myelodysplastic syndromes and induces TLR4-mediated cytokine production. Haematologica. 2013;98(8):1206-1215.
33. Boxer L, Dale DC. Neutropenia: causes and consequences. Semin Hematol. 2002;39(2):75-81. (Pubitemid 34298829)
34. Gersuk GM, Beckham C, Loken MR, et al. A role for tumour necrosis factor-alpha, Fas and Fas-Ligand in marrow failure associated with myelodysplastic syndrome. Br J Haematol. 1998;103(1):176-188. (Pubitemid 28470816)
35. Zang DY, Goodwin RG, Loken MR, Bryant E, Deeg HJ. Expression of tumor necrosis factor-related apoptosis-inducing ligand, Apo2L, and its receptors in myelodysplastic syndrome: effects on in vitro hemopoiesis. Blood. 2001;98(10):3058-3065.
36. Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol. 2002;20:197-216. (Pubitemid 34293424)
37. Barton GM, Medzhitov R. Control of adaptive immune responses by Toll-like receptors. Curr Opin Immunol. 2002;14(3):380-383. (Pubitemid 34327982)
38. Lindsley RC, Ebert BL. Molecular pathophysiology of myelodysplastic syndromes. Annu Rev Pathol. 2013;8:21-47.
39. Enomoto N, Takei Y, Hirose M, et al. Thalidomide prevents alcoholic liver injury in rats through suppression of Kupffer cell sensitization and TNF-a production. Gastroenterology. 2002;123(1):291-300. (Pubitemid 34747549)
40. Stone RM. How I treat patients with myelodysplastic syndromes. Blood. 2009;113(25):6296-6303.